Source: Annual Congress 2002 - Pneumonias: aetiology; management; antimicrobial resistance; empyema
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
R. Menéndez, A. Torres, on Behalf of Neumofail Group (Valencia, Barcelona, Spain). Predictor factors of empirical antimicrobial treatment failure in community-acquired pneumonia. Eur Respir J 2002; 20: Suppl. 38, 2208

Member's Comments

No comment yet.

Related content which might interest you: Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia Source: Eur Respir J 2011; 37: 1332-1339 Year: 2011 The approach to antibiotic treatment in community-acquired pneumonia Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia Year: 2008 Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia Source: Eur Respir Rev 2007; 16: 45-49 Year: 2007 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Cost of treatment failure in community-acquired pneumonia Source: Eur Respir J 2007; 30: Suppl. 51, 195s Year: 2007 Treatment failure of community-acquired pneumonia: risk factors and consequences Source: Annual Congress 2012 - PG17 Clinical failure of treatment of respiratory infections Year: 2012 Antibiotic treatment for nosocomial pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211 Year: 2004 Aspiration risks factors, microbiology and empiric antibiotics for patients hospitalized with community-acquired pneumonia Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia Source: Eur Respir J, 50 (3) 1602306; 10.1183/13993003.02306-2016 Year: 2017 Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia Source: Eur Respir Rev 2007; 16: 33-39 Year: 2007 Empirical treatment of community-acquired pneumonia after outpatient beta-lactam therapy Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Risk factors for drug-resistant pathogens in patients with hospital-acquired and ventilator-associated pneumonia Source: International Congress 2017 – Respiratory infections in critically ill and immuno-depressed patientes Year: 2017 The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 733s Year: 2006 Hospital-acquired pneumonia: microbiological data and potential adequacy of antimicrobial regimens Source: Eur Respir J 2002; 20: 432-439 Year: 2002 Risk factors of paediatric community-acquired pneumonia Source: Eur Respir J 2011; 37: 724-725 Year: 2011 Impact of guidelines on HAP and VAP outcomes Source: Eur Respir Mon 2011; 53: 66-73 Year: 2011 Ventilator-associated pneumonia due to colistin susceptible-only microorganisms Source: Eur Respir J 2007; 30: 307-313 Year: 2007 Changes in empirical initial antibiotic therapy in community-acquired pneumonia: assessment of clinical failure versus discordant therapy Source: Eur Respir J 2006; 28: Suppl. 50, 736s Year: 2006 Clinical failure in community-acquired pneumonia Source: International Congress 2014 – PG16 Low respiratory tract infections: learning from real clinical cases Year: 2014